- Continued improvement in revenues and cost savings
- Margins remain high in the local services
- US growing with THRiV in high demand from pharma
- No mention of Charac (UK)
- FY23H2 was $34M (roughly even between quarters)
- FY24Q3 revenue $24M may project same or more in Q4 (FY Revenue ~$125M)
- MDR market cap $150M with above FY revenue estimate ($125M)
- ALC market cap $60M on $35M annual revenue (if lucky!)
- Management have demonstrated YoY growth for a number of years
- Will Luke and Claude change their tune?
- Will the market recognise profitability and success in the US?
Continued improvement in revenues and cost savings Margins...
Add MDR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
31.0¢ |
Change
0.005(1.64%) |
Mkt cap ! $170.5M | |||
| Open | High | Low | Value | Volume |
| 30.5¢ | 31.0¢ | 30.0¢ | $133.7K | 439.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10000 | 29.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 31062 | 2 |
View Market Depth
| Last trade - 16.10pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
30.0¢ |
Change
0.005 ( 3.59 %) |
||||
| Open | High | Low | Volume | ||
| 30.5¢ | 31.0¢ | 30.0¢ | 63006 | ||
| Last updated 15.40pm 03/05/2024 ? | |||||
| MDR (ASX) Chart |